Comparative evaluation of the ExaVir load version 3 reverse transcriptase assay for measurement of human immunodeficiency virus type 1 plasma load

Journal of Clinical Microbiology

Volumn 47, Issue 10, 2009, Pages 3266-3270

  Labbett, Wendy ^a   Garcia Diaz, Ana ^a   Fox, Zoe ^a   Clewley, Gillian S ^a   Fernandez, Thomas ^a   Johnson, Margaret ^a   Geretti, Anna Maria ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; PLASMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; VIRUS LOAD;

ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; PLASMA; REAGENT KITS, DIAGNOSTIC; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 70349646098     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00715-09     Document Type: Article

References (25)

1. Bagchi, S., M. C. Kempf, A. O. Westfall, A. Maherya, J. Willig, and M. S. Saag. 2007. Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? Clin. Infect. Dis. 44:135-138.
2. Bracciale, L., S. Di Giambenedetto, M. Colafigli, G. La Torre, M. Prosperi, R. Santangelo, S. Marchetti, R. Cauda, G. Fadda, and A. De Luca. 2009. Virological suppression reduces clinical progression in patients with multiclass- resistant HIV type 1. AIDS Res. Hum. Retrovir. 25:261-267.
3. Braun, J., J. C. Plantier, M. F. Hellot, E. Tuaillon, M. Gueudin, F. Damond, A. Malmsten, G. E. Corrigan, and F. Simon. 2003. A new quantitative HIV load assay based on plasma virion reverse transcriptase activity for the different types, groups and subtypes. AIDS 17:331-336. (Pubitemid 36223257)
4. Colebunders, R., K. R. Moses, J. Laurence, H. M. Shihab, F. Semitala, F. Lutwama, S. Bakeera-Kitaka, L. Lynen, L. Spacek, S. J. Reynolds, T. C. Quinn, B. Viner, and H. Mayanja-Kizza. 2006. A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries. Lancet Infect. Dis. 6:53-59.
5. Iqbal, H. S., P. Balakrishnan, A. J. Cecelia, S. Solomon, N. Kumarasamy, V. Madhavan, K. G. Murugavel, A. K. Ganesh, S. S. Solomon, K. H. Mayer, and S. M. Crowe. 2007. Use of an HIV-1 reverse-transcriptase enzyme-activity assay to measure HIV-1 viral load as a potential alternative to nucleic acid-based assay for monitoring antiretroviral therapy in resource-limited settings. J. Med. Microbiol. 56:1611-1614.
6. Garcia-Diaz, A., G. S. Clewley, C. L. Booth, W. Labett, N. McAllister, and A. M. Geretti. 2006. Comparative evaluation of the performance of the Abbott real-time human immunodeficiency virus type 1 (HIV-1) assay for measurement of HIV-1 plasma viral load following automated specimen preparation. J. Clin. Microbiol. 44:1788-1791.
7. Geretti, A. M. 2007. Epidemiology of antiretroviral drug resistance in drug-naïve persons. Curr. Opin. Infect. Dis. 20:22-32.
8. Goldie, S. J., Y. Yazdanpanah, E. Losina, M. C. Weinstein, X. Anglaret, R. P Walensky, H. E. Hsu, A. Kimmel, C. Holmes, J. E. Kaplan, and K. A. Freedberg. 2006. Cost-effectiveness of HIV treatment in resource-poor settings - the case of Cote d'Ivoire. N. Engl. J. Med. 355:1141-1153.
9. Greengrass, V., M. Plate, P. Steele, J. Denholm, C. L. Cherry, L. Morris, and S. M. Crowe. 2008. Evaluation of the new version 3 Cavidi ExaVir Load quantitative HIV RT load kit as an alternative HIV viral load monitoring assay for use in Melbourne, Australia. Abstr. 17th Int. AIDS Conf., abstr. THPE0054.
10. Gueudin, M., J. C. Plantier, V. Lemee, M. P. Schmitt, L. Chartier, T. Bourlet, A. Ruffault, F. Damond, M. Vray, and F. Simon. 2007. Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes. J. Acquir. Immune Defic. Syndr. 44:500-505.
11. Hughes, M. D., V. A. Johnson, M. S. Hirsch, J. W. Bremer, T. Elbeik, A. Erice, D. R. Kuritzkes, W. A. Scott, S. A. Spector, N. Basgoz, M. A. Fischl, R. T. D'Aquila, et al. 1997. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. Ann. Intern. Med. 126:929-938.
12. Jennings, C., S. A. Fiscus, S. M. Crowe, A. D. Danilovic, R. J. Morack, S. Scianna, A. Cachafeiro, D. J. Brambilla, J. Schupbach, W. Stevens, R. Respess, O. E. Varnier, G. E. Corrigan, J. S. Gronowitz, M. A. Ussery, and J. W. Bremer. 2005. Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay. J. Clin. Microbiol. 43:5950-5956.
13. Kumarasamy, N., S. Solomon, S. K. Chaguturu, A. J. Cecelia, S. Vallabhaneni, T. P. Flanigan, and K. H. Mayer. 2005. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Clin. Infect. Dis. 41:1525-1528.
14. Lombart, J. P., M. Vray, A. Kafando, V. Lemée, R. Ouédraogo-Traoré, G. E. Corrigan, J. C. Plantier, F. Simon, and J. Braun. 2005. Plasma virion reverse transcriptase activity and heat dissociation-boosted p24 antigen assay for HIV load in Burkina Faso, West Africa. AIDS 19:1273-1277.
15. Malmsten, A., X. W. Shao, S. Sjödahl, E. l. Fredriksson, I. Pettersson, T. Leitner, C. F. Källander, E. Sandström, and J. S. Gronowitz. 2005. Improved HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma. J. Med. Virol. 76:291-296.
16. Manavi, K. 2008. The significance of low level plasma HIV viral load on COBAS TaqMan HIV-1 assay for patients with undetectable plasma viral load on COBAS Amplicor Monitor version 1.5. HIV Clin. Trials 9:283-286.
17. Moore, D. M., A. Awor, R. Downing, J. Kaplan, J. S. Montaner, J. Hancock, W. Were, and J. Mermin. 2008. CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 49:477-4484.
18. Murri, R., A. C. Lepri, P. Cicconi, A. Poggio, M. Arlotti, G. Tositti, D. Santoro, M. L. Soranzo, G. Rizzardini, V. Colangeli, M. Montroni, and A. D. Monforte. 2006. Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral- naïve patients study. J. Acquir. Immune Defic. Syndr. 41:23-30.
19. Phillips, A. N., D. Pillay, A. H. Miners, D. E. Bennett, C. F. Gilks, and J. D. Lundgren. 2008. Outcomes from monitoring patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count or clinical observation alone: a computer simulation model. Lancet 371:1443-1451.
20. Reynolds, S. J., G. Nakigozi, K. Newell, A. Ndyanabo, R. Galiwongo, I. Boaz, T. C. Quinn, R. Gray, M. Wawer, and D. Serwadda. 2009. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 23:697-700.
21. Schutten, M., D. Peters, N. K. T. Back, M. Beld, K. Beuselinck, V. Foulongne, A. M. Geretti, L. Pandiani, C. Tiemann, and H. G. Niesters. 2007. Multicenter evaluation of the new Abbott RealTime assay for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J. Clin. Microbiol. 45:1712-1717.
22. Severe, P., P. Leger, M. Charles, F. Noel, G. Bonhomme, G. Bois, E. George, S. Kenel-Pierre, P. F. Wright, R. Gulick, W. D. Johnson, Jr., J. W. Pape, and D. W. Fitzgerald. 2005. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N. Engl. J. Med. 353:2325-2334.
23. Sivapalasingam, S., S. Essajee, P. N. Nyambi, V. Itri, B. Hanna, R. Holzman, and F. Valentine. 2005. Human immunodeficiency virus (HIV) reverse transcriptase activity correlates with HIV RNA load: implications for resourcelimited settings. J. Clin. Microbiol. 43:3793-3796.
24. Steegen, K., S. Luchters, N. De Cabooter, J. Reynaerts, K. Mandaliya, J. Plum, W. Jaoko, C. Verhofstede, and M. Temmerman. 2007. Evaluation of two commercially available alternatives for HIV-1 viral load testing in resource-limited settings. J. Virol. Methods 146:178-187. (Pubitemid 350026632)
25. Stevens, G., N. Rekhviashvili, L. E. Scott, R. Gonin, and W. Stevens. 2005. Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. J. Clin. Microbiol. 43:857-861.